Taysha Gene Therapies (Taysha Gene Therapies) Net-Net Working Capital : $0.13 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Taysha Gene Therapies's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $0.13.

The industry rank for Taysha Gene Therapies's Net-Net Working Capital or its related term are showing as below:

TSHA's Price-to-Net-Net-Working-Capital is ranked worse than
90.37% of 924 companies
in the Biotechnology industry
Industry Median: 4.275 vs TSHA: 26.38

Taysha Gene Therapies Net-Net Working Capital Historical Data

The historical data trend for Taysha Gene Therapies's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies Net-Net Working Capital Chart

Taysha Gene Therapies Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net-Net Working Capital

6.45

0.79

-0.59

0.25

Taysha Gene Therapies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net-Net Working Capital	Get a 7-Day Free Trial													-0.84	-1.14	-0.43	0.25	0.13

Competitive Comparison of Taysha Gene Therapies's Net-Net Working Capital

For the Biotechnology subindustry, Taysha Gene Therapies's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taysha Gene Therapies's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's Price-to-Net-Net-Working-Capital falls into.

Taysha Gene Therapies Net-Net Working Capital Calculation

Taysha Gene Therapies's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

	Net-Net Working Capital		(A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(143.94	+	0.75 * 0	+	0.5 * 0	-	97.794
-	0	-	0)	/	186.96
=	0.25

Taysha Gene Therapies's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

	Net-Net Working Capital		(Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(123.98	+	0.75 * 0	+	0.5 * 0	-	99.15
-	0	-	0)	/	187.018
=	0.13

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Taysha Gene Therapies (NAS:TSHA) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Taysha Gene Therapies Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247

Website

https://www.tayshagtx.com

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Executives

Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long	director	KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam	officer: Chief Financial Officer	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii	10 percent owner	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc.	10 percent owner	2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc.	10 percent owner	600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad	officer: CMO and Head of R&D	C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino	director	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape	director	C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235